tru Independence’s Core Laboratories CLB Stock Holding History

tru Independence’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75	Closed	-$2K	–	415
2020 Q2	$2K	Hold	75	–	–	﹤0.01%	789
2020 Q1	$1K	Hold	75	–	–	﹤0.01%	668
2019 Q4	$1K	Buy	+75	New	+$3.37K	﹤0.01%	857

Other funds holding CLB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AKO Capital London, United Kingdom $4.29B AUM 4.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

tru Independence's CLB Position: Q3 2020 in Review

tru Independence sold out of Core Laboratories (CLB) in Q3 2020, closing a stake of 75 shares — an estimated $2K sold.

tru Independence first reported a position in CLB in Q4 2019 and held it in 3 quarters. The position peaked at $2K in Q2 2020. 187 funds tracked by Wall St. Rank hold CLB as of Q3 2020.

tru Independence reported no remaining Core Laboratories position as of Q3 2020 after selling out during the quarter.
tru Independence sold 75 Core Laboratories shares in Q3 2020, an estimated $2K.
tru Independence first reported a position in Core Laboratories in Q4 2019 and held it in 3 quarters.
tru Independence's Core Laboratories position peaked at $2K in Q2 2020.
187 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.